<scp>GLP</scp> ‐ <scp>1R</scp> biased <scp>cAMP</scp> agonism maintains glycemic control with reduced malaise and emesis in preclinical mammalian models
Collectively, Ex-Phe1 maintains glycemic benefits in all three species, but putatively blunts the ability of the CNS GLP-1R+ cells to drive anorexia and weight loss, as well as unwanted adverse events (nausea/emesis) in rats and musk shrews.
Authors
- T Coskun
- Matthew P. Coghlan (ORCID: https://orcid.org/0000-0002-0894-1505)
- KYLE SLOOP
- Amy Xiao (ORCID: https://orcid.org/0000-0001-7405-0260)
- Bart De Jonghe
- Erik T. Bodor
- Alex D. White (ORCID: https://orcid.org/0000-0003-2180-2136)
- Sarah V. Applebey (ORCID: https://orcid.org/0000-0002-8162-8785)
- Danya Aldaghma
- Matthew Hayes
- Allison M. Pataro (ORCID: https://orcid.org/0009-0009-3933-3084)
- Allaha Z. Mohiby
- Minrong Ai
- Yuewei Qian
- Libbey S. O'Farrell
- Tito Borner
- Brandon Alonso
- Robert P. Doyle
- Caitlin Baumer‐Harrison
Institutions
- University of Southern California (US)
- Eli Lilly (United States) (US)
- SUNY Upstate Medical University (US)
- Syracuse University (US)
- University of Pennsylvania (US)
Publication Details
- Journal
- Diabetes Obesity and Metabolism
- Published
- 2026-01-08
- DOI
- https://doi.org/10.1111/dom.70427
- Citations
- 2
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 61.46
Funders
- Eli Lilly and Company
- University of Pennsylvania
- National Institutes of Health
- Perelman School of Medicine, University of Pennsylvania